Evaluate also projects a major bump in sales for AstraZeneca from $50.9 billion to $64.4 billion in 2030, thanks in part to Daiichi Sankyo-partnered ADC cancer drug Enhertu, which has been pegged ...

AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by AstraZeneca in the DESTINY-Endometrial01 phase 3 trial. AstraZeneca is ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

NEW YORK – The US Food and Drug Administration on Thursday approved Merck's PD-1 inhibitor Keytruda (pembrolizumab) as a perioperative treatment for patients with resectable, locally advanced head and ...

President Trump said he thinks he could make amends with tech billionaire Elon Musk following their public feud, but doing so is not a priority for him. Trump was asked by the New York Post’s ...

Enhertu (5.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ...

Hanwha Systems, a leading Korean defense and aerospace technology company, announced Tuesday that it signed a memorandum of understanding (MOU) with BAE Systems, a premier British defense and ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows. A potential new first-line treatment option for patients ...